BPC-157 and GHK-Cu are both discussed in tissue-repair and regeneration contexts, but they are very different molecules with different research histories. BPC-157 is a synthetic peptide studied mostly in animal models of tendon and gut healing, while GHK-Cu is a naturally occurring copper tripeptide studied mainly in skin, wound, and cosmetic settings. Neither is FDA-approved for the uses people ask about, so this comparison is about framing expectations rather than picking a winner.
Reviewed for accuracy · Last reviewed July 7, 2026For BPC-157, the review literature is explicit that its healing effects, while consistent across many animal studies, have not been confirmed in humans. Its evidence base centers on rodent models of tendon, muscle, and gut injury rather than controlled human trials.
GHK-Cu has a different research history: it is a copper tripeptide characterized in cell and animal work and studied in skin repair and wound-healing contexts, and it is widely used as a cosmetic ingredient. That cosmetic use is not the same as approval as a drug for internal tissue repair, so its human evidence for the systemic uses people ask about is also limited.
Because these compounds were studied for different tissues (BPC-157 largely internal and musculoskeletal, GHK-Cu largely skin), they are not really interchangeable, and neither has the human trial base to support firm efficacy claims. Product quality is a practical, real-world concern for both when sold as research chemicals.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting any compound.